SYNTHESIS OF 9-(3-HYDROXYPROPOXY)CUANINE, A NOVEL ANTIVIRAL ACYCLONUCLEOSIDE

M.R. Harnden,\* A. Parkin and P.G. Wyatt

Beecham Pharmaceuticals Research Division, Biosciences Research Centre, Great Burgh, Epsom, Surrey KT18 5XQ, U.K.

ABSTRACT: Synthetic approaches to 9-(3-hydroxypropoxy)guanine  $(\underline{2})$  involving the intermediacy of either a 1-alkoxyimidazole  $(\underline{7})$  or a 4-alkoxyaminopyrimidine  $(\underline{13})$  are described. This 9-alkoxyguanine  $(\underline{2})$  has potent and selective anti-herpesvirus activity and is the first reported member of a new series of antiviral acyclonucleosides.

As part of our studies on the synthesis and antiviral evaluation of novel acyclonucleosides, 1-5 we have prepared 9-(3-hydroxypropoxy)guanine (2), an isomer of 9-[(2-hydroxyethoxy)methyl]guanine (1, acyclovir)<sup>6-8</sup> in which the atom attached to N9 of guanine is oxygen.



Our initial synthetic approach to 2 (Scheme 1) was based upon a published route to 9-hydroxyguanine via 5-amino-1-benzyloxy-4-carbamoylimidazole.<sup>9</sup>

3-Benzyloxypropoxyamine (5) was prepared in 73% overall yield by condensation of the monobenzyl ether of propane-1,3-diol (3) with N-hydroxyphthalimide,<sup>10</sup> followed by reaction with hydrazine hydrate. The alkoxyamine 5 was then reacted at room temperature with ethyl N-(carbamoylcyano)methylformimidate (6)<sup>9</sup> in methanol-ether to afford, after column chromatography on silica gel, the 1-alkoxyimidazole 7 in 15% yield: mp 139-141°C (from acetone-petroleum ether);  $\lambda_{max}$  (EtOH) 264 ( $\varepsilon$  13,400)nm;  $\delta_{\rm H}$  [(CD3)2SO] 1.98 (2H, quintet, J 6.5Hz, CH2CH2CH2), 3.59 (2H, t, J 6.5Hz, CH2OCH2Ph), 4.22 (2H, t, J 6.5Hz, CH2ON), 4.49 (2H, s, CH2Ph), 5.81 (2H, br.s, CNH2), 6.71 (2H, br.s, CONH2), 7.34 (6H, m, 2-H and C6H5). Found: C, 58.02; H, 6.31; N, 19.33%; M<sup>+</sup> 290.1378. C14H18N4O3 requires: C, 57.91; H, 6.26; N, 19.30%; M<sup>+</sup> 290.1379.

Using the same sequence of reactions as had been used previously to prepare 9-benzyloxyguanine<sup>9</sup>, 7 was converted to 9-(3-benzyloxypropoxy)guanine (8) in 29% overall yield. Hydrogenolysis of 8 in 80% formic acid in the presence of 10% Pd on charcoal then provided the required 3-hydroxypropoxy derivative 2 in 89% yield: mp 275-276°C decomp (from water);  $\lambda_{max}$  (H<sub>2</sub>O) 253  $\epsilon$  (13,600)nm;  $\delta_{\rm H}$  [(CD<sub>3</sub>)<sub>2</sub>SO] 1.80 (2H, quintet, J 6.6Hz and 6.0Hz





CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 3.55 (2H, q, J 5.5Hz and 6.0Hz, CH<sub>2</sub>OH), 4.32 (2H, t, J 6.6Hz, CH<sub>2</sub>ON), 4.57 (1H, t, J 5.5Hz, D<sub>2</sub>O exchangeable OH), 6.57 (2H, br.s, D<sub>2</sub>O exchangeable NH<sub>2</sub>), 7.91 (1H, s, 8-H), 10.63 (1H, br.s, D<sub>2</sub>O exchangeable NH). Found: C, 41.33; H, 5.20; N, 30.24%; M<sup>+</sup> 225.0874. C<sub>8</sub>H<sub>11</sub>N<sub>5</sub>O<sub>3</sub>.0.4 H<sub>2</sub>O requires: C, 41.33; H, 5.13; N, 30.14%; M<sup>+</sup> 225.0862.

In antiviral tests carried out in Vero and MRC-5 cell cultures 9-(3-hydroxypropoxy)guanine (2) had an IC<sub>50</sub> (50% inhibitory concentration) for inhibition of the replication of herpes simplex virus types 1 and 2  $\approx$  0.3µg/ml (cf. acyclovir IC<sub>50</sub>  $\approx$  0.9µg/ml) and against varicella zoster virus 2 had an IC<sub>50</sub>  $\approx$  0.8µg/ml (cf. acyclovir IC<sub>50</sub>  $\approx$  3.8µg/ml). No effect upon uninfected cell monolayers was observed in the presence of concentrations of 2 up to 100µg/ml.

These interesting biological properties prompted us to investigate more efficient procedures for synthesis of  $\underline{2}$  (Scheme 2). Brief reaction of the protected alkoxyamine <u>5</u> with N,N-dimethylformamide dimethyl acetal at room temperature afforded the dimethylformamidine <u>9</u>, which was isolated as an oil in 92% yield:  $\delta_{\rm H}$  (CDCl<sub>3</sub>) 1.95 (2H, m, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 2.76 (6H, s, 2 x CH<sub>3</sub>), 3.57 (2H, t, J 6.5Hz, CH<sub>2</sub>OCH<sub>2</sub>Ph), 3.95 (2H, t, J 6.5Hz, CH<sub>2</sub>ON), 4.51 (2H, s, CH<sub>2</sub>Ph), 7.30 (5H, m, C<sub>6</sub>H<sub>5</sub>), 7.61 (1H, s, CH). Found: M<sup>+</sup> 236.1527. Cl<sub>3</sub>H<sub>2</sub>ON<sub>2</sub>O<sub>2</sub> requires: M<sup>+</sup> 236.1524. Reaction of <u>9</u> with aminocyanoacetamide hydrochloride in methanol at room temperature gave the amidine 10 as a mixture of geometric isomers, isolated as an unstable oil in 70% yield:  $\delta_{\rm H}$  [(CD3)2SO] 1.86 (2H, m, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 3.53 (2H, m, CH<sub>2</sub>OCH<sub>2</sub>Ph), 3.85 and 3.94 (2H, 2t, J 6.5Hz, CH<sub>2</sub>ON), 4.46 (2H, s, CH<sub>2</sub>Ph), 5.06 and 5.23 (1H, 2d, J 8Hz, CHCN), 6.76 (1H, d, J 10.5Hz, -CH), 6.95 (1H, dd, J 10.5Hz and 8Hz, D<sub>2</sub>O exchangeable NH), 7.2-7.4 (5H, m, C<sub>6</sub>H<sub>5</sub>), 7.95 (2H, s, D<sub>2</sub>O exchangeable NH<sub>2</sub>). Found: M<sup>+</sup> 290.1369.C<sub>14</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub> requires: M<sup>+</sup> 290.1376. Attempted cyclisation of <u>10</u> using either mineral or organic acids gave complex mixtures of products and low yields of the 1-alkoxyimidazole <u>7</u>. However, in the presence of the Lewis acid boron trifluoride etherate, in 1,2-dimethoxyethane at 60-80°C <u>10</u> cyclised cleanly to afford <u>7</u> in 63% yield.

Thus, using these adaptations we were able to increase the overall yield for conversion of  $5 - \frac{5}{7}$  from 15% to 40%. However, there still remained the problem of conversion of  $\frac{7}{7}$  to the guanine  $\frac{8}{5}$ , which we had never achieved in greater than 30% overall yield.

For this reason we also explored an alternative synthesis of  $\underline{2}$  via pyrimidine intermediates (Scheme 3). Although displacement of chloride from 2,5-diamino-4,6-dichloropyrimidine (<u>11</u>)<sup>11</sup> with the alkoxyamine 5 did not occur readily, <u>11</u> was converted in 70% yield to its di-N-formyl derivative <u>12</u>, which in the presence of triethylamine reacted in refluxing dioxane with <u>5</u> to afford, after column chromatography on silica gel, the alkoxyaminopyrimidine <u>13</u> in 51% yield:  $\delta_{\rm H}$  [(CD<sub>3</sub>)<sub>2</sub>SO] 1.88 (2H, quintet, J 6.3Hz, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 3.57 (2H, t, J 6.3Hz, CH<sub>2</sub>OCH<sub>2</sub>Ph), 3.95 (2H, t, J 6.3Hz, CH<sub>2</sub>ON), 4.47 (2H, s, CH<sub>2</sub>Ph), 7.32 (5H, m, C<sub>6</sub>H<sub>5</sub>), 8.14 (1H, s, HCON), 9.26 (1H, s, HCON), 9.42 (1H, br.s, D<sub>2</sub>O exchangeable, N<u>HO</u>CH<sub>2</sub>), 10.83 (2H, br.s, 2 x HCON<u>H</u>). Found: M<sup>+</sup> 379.1026.C<sub>16</sub>H<sub>18</sub>N<sub>5</sub>O<sub>4</sub>Cl

Scheme 2



requires: M<sup>+</sup> 379.1047. Closure of the imidazole ring by heating at 120°C with diethoxymethyl acetate,<sup>12</sup> followed by treatment with ammonia in methanol, then gave the 6-chloropurine derivative <u>14</u>, isolated in 95% yield after column chromatography on silica gel:  $\delta_{\rm H}$  (CDCl<sub>3</sub>) 2.15 (2H, quintet, J 6Hz, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>), 3.75 (2H, t, J 6Hz, CH<sub>2</sub>OCH<sub>2</sub>Ph), 4.55 (4H, m, CH<sub>2</sub>ON, CH<sub>2</sub>Ph), 7.40 (5H, m, C<sub>6</sub>H<sub>5</sub>), 8.10 (1H, s, 8-H), 8.40 (1H, d, J 10Hz, D<sub>2</sub>O exchangeable, HCON<u>H</u>), 9.60 (1H, d, J 10Hz, H<u>C</u>ONH). Found: M<sup>+</sup> 361.0942. C<sub>16</sub>H<sub>16</sub>N<sub>5</sub>O<sub>3</sub>Cl requires: M<sup>+</sup> 361.0942. Hydrolysis of the 6-chloro group of <u>14</u> in 80% formic acid at 100°C, followed by hydrogenolysis of the 0-benzyl protecting group in the presence of 10% Pd on charcoal and removal of the N2-formyl group with aqueous ammonia at 100°C, then afforded the guanine derivative 2 in 39% overall yield.



This route (Scheme 3) is shorter and more efficient than the route via imidazole intermediates (Schemes 1 and 2) and has been used in syntheses of additional antiviral N9-alkoxyguanines, which will be reported in subsequent publications.

14

ACKNOWLEDGEMENTS: We thank Mr. M.R. Boyd and his colleagues for the antiviral data and Dr. M. Cole for his interest in, and encouragement for these studies.

## REFERENCES

- 1. A. Parkin and M.R. Harnden, J. Heterocyclic Chem., 19, 33 (1982).
- 2. S. Bailey, C.T. Shanks and M.R. Harnden, Nucleosides and Nucleotides, 4, 565, (1985).
- 3. S. Bailey and M.R. Harnden, Nucleosides and Nucleotides, 6, 555 (1987).
- 4. M.R. Harnden and R.L. Jarvest, <u>Tetrahedron Letters</u>, <u>26</u>, 4265 (1985).
- 5. M.R. Harnden, R.L. Jarvest, T.H. Bacon and M.R. Boyd, J. Med. Chem., 30, 1636, (1987).
- H.J. Schaeffer, L. Beauchamp, P. De Miranda, G.B. Elion, D.J. Bauer and P. Collins, <u>Nature</u>, <u>272</u>, 583 (1978).
- G.B. Elion, P.A. Furman, J.A. Fyfe, P. De Miranda, L. Beauchamp and H.J. Schaeffer, <u>Proc. Natl. Acad. U.S.A.</u>, 74, 5716 (1977).
- 8. P. Collins and D.J. Bauer, J. Antimicrob. Chemother., 5, 431 (1979).
- 9. A.A. Watson, J. Org. Chem., 39, 2911 (1974).

2

- 10. E. Grochowski and J. Jurczak, Synthesis., 10, 682 (1976).
- 11. C. Temple Jr., B.H. Smith and J.A. Montgomery, J. Org. Chem., 40, 3141 (1975).
- J.A. Montgomery and C. Temple Jr., <u>J. Amer. Chem. Soc.</u>, <u>79</u>, 5238 (1957). (Received in UK 27 November 1987)